pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-758 |
Genomic Coordinates | chr14: 101026020 - 101026107 |
Synonyms | MIRN758, hsa-mir-758, MIR758 |
Description | Homo sapiens miR-758 stem-loop |
Comment | None |
RNA Secondary Structure | |
Associated Diseases |
Mature miRNA Information | ||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-758-5p | |||||||||||||||||||||||||||||||||||||||||||||
Sequence | 15| GAUGGUUGACCAGAGAGCACAC |36 | |||||||||||||||||||||||||||||||||||||||||||||
Evidence | Experimental | |||||||||||||||||||||||||||||||||||||||||||||
Experiments | SOLiD | |||||||||||||||||||||||||||||||||||||||||||||
Editing Events in miRNAs |
|
|||||||||||||||||||||||||||||||||||||||||||||
SNPs in miRNA |
|
|||||||||||||||||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | CCND1 | ||||||||||||||||||||
Synonyms | BCL1, D11S287E, PRAD1, U21B31 | ||||||||||||||||||||
Description | cyclin D1 | ||||||||||||||||||||
Transcript | NM_053056 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on CCND1 | |||||||||||||||||||||
3'UTR of CCND1 (miRNA target sites are highlighted) |
>CCND1|NM_053056|3'UTR 1 GGGCGCCAGGCAGGCGGGCGCCACCGCCACCCGCAGCGAGGGCGGAGCCGGCCCCAGGTGCTCCCCTGACAGTCCCTCCT 81 CTCCGGAGCATTTTGATACCAGAAGGGAAAGCTTCATTCTCCTTGTTGTTGGTTGTTTTTTCCTTTGCTCTTTCCCCCTT 161 CCATCTCTGACTTAAGCAAAAGAAAAAGATTACCCAAAAACTGTCTTTAAAAGAGAGAGAGAGAAAAAAAAAATAGTATT 241 TGCATAACCCTGAGCGGTGGGGGAGGAGGGTTGTGCTACAGATGATAGAGGATTTTATACCCCAATAATCAACTCGTTTT 321 TATATTAATGTACTTGTTTCTCTGTTGTAAGAATAGGCATTAACACAAAGGAGGCGTCTCGGGAGAGGATTAGGTTCCAT 401 CCTTTACGTGTTTAAAAAAAAGCATAAAAACATTTTAAAAACATAGAAAAATTCAGCAAACCATTTTTAAAGTAGAAGAG 481 GGTTTTAGGTAGAAAAACATATTCTTGTGCTTTTCCTGATAAAGCACAGCTGTAGTGGGGTTCTAGGCATCTCTGTACTT 561 TGCTTGCTCATATGCATGTAGTCACTTTATAAGTCATTGTATGTTATTATATTCCGTAGGTAGATGTGTAACCTCTTCAC 641 CTTATTCATGGCTGAAGTCACCTCTTGGTTACAGTAGCGTAGCGTGCCCGTGTGCATGTCCTTTGCGCCTGTGACCACCA 721 CCCCAACAAACCATCCAGTGACAAACCATCCAGTGGAGGTTTGTCGGGCACCAGCCAGCGTAGCAGGGTCGGGAAAGGCC 801 ACCTGTCCCACTCCTACGATACGCTACTATAAAGAGAAGACGAAATAGTGACATAATATATTCTATTTTTATACTCTTCC 881 TATTTTTGTAGTGACCTGTTTATGAGATGCTGGTTTTCTACCCAACGGCCCTGCAGCCAGCTCACGTCCAGGTTCAACCC 961 ACAGCTACTTGGTTTGTGTTCTTCTTCATATTCTAAAACCATTCCATTTCCAAGCACTTTCAGTCCAATAGGTGTAGGAA 1041 ATAGCGCTGTTTTTGTTGTGTGTGCAGGGAGGGCAGTTTTCTAATGGAATGGTTTGGGAATATCCATGTACTTGTTTGCA 1121 AGCAGGACTTTGAGGCAAGTGTGGGCCACTGTGGTGGCAGTGGAGGTGGGGTGTTTGGGAGGCTGCGTGCCAGTCAAGAA 1201 GAAAAAGGTTTGCATTCTCACATTGCCAGGATGATAAGTTCCTTTCCTTTTCTTTAAAGAAGTTGAAGTTTAGGAATCCT 1281 TTGGTGCCAACTGGTGTTTGAAAGTAGGGACCTCAGAGGTTTACCTAGAGAACAGGTGGTTTTTAAGGGTTATCTTAGAT 1361 GTTTCACACCGGAAGGTTTTTAAACACTAAAATATATAATTTATAGTTAAGGCTAAAAAGTATATTTATTGCAGAGGATG 1441 TTCATAAGGCCAGTATGATTTATAAATGCAATCTCCCCTTGATTTAAACACACAGATACACACACACACACACACACACA 1521 CAAACCTTCTGCCTTTGATGTTACAGATTTAATACAGTTTATTTTTAAAGATAGATCCTTTTATAGGTGAGAAAAAAACA 1601 ATCTGGAAGAAAAAAACCACACAAAGACATTGATTCAGCCTGTTTGGCGTTTCCCAGAGTCATCTGATTGGACAGGCATG 1681 GGTGCAAGGAAAATTAGGGTACTCAACCTAAGTTCGGTTCCGATGAATTCTTATCCCCTGCCCCTTCCTTTAAAAAACTT 1761 AGTGACAAAATAGACAATTTGCACATCTTGGCTATGTAATTCTTGTAATTTTTATTTAGGAAGTGTTGAAGGGAGGTGGC 1841 AAGAGTGTGGAGGCTGACGTGTGAGGGAGGACAGGCGGGAGGAGGTGTGAGGAGGAGGCTCCCGAGGGGAAGGGGCGGTG 1921 CCCACACCGGGGACAGGCCGCAGCTCCATTTTCTTATTGCGCTGCTACCGTTGACTTCCAGGCACGGTTTGGAAATATTC 2001 ACATCGCTTCTGTGTATCTCTTTCACATTGTTTGCTGCTATTGGAGGATCAGTTTTTTGTTTTACAATGTCATATACTGC 2081 CATGTACTAGTTTTAGTTTTCTCTTAGAACATTGTATTACAGATGCCTTTTTTGTAGTTTTTTTTTTTTTTATGTGATCA 2161 ATTTTGACTTAATGTGATTACTGCTCTATTCCAAAAAGGTTGCTGTTTCACAATACCTCATGCTTCACTTAGCCATGGTG 2241 GACCCAGCGGGCAGGTTCTGCCTGCTTTGGCGGGCAGACACGCGGGCGCGATCCCACACAGGCTGGCGGGGGCCGGCCCC 2321 GAGGCCGCGTGCGTGAGAACCGCGCCGGTGTCCCCAGAGACCAGGCTGTGTCCCTCTTCTCTTCCCTGCGCCTGTGATGC 2401 TGGGCACTTCATCTGATCGGGGGCGTAGCATCATAGTAGTTTTTACAGCTGTGTTATTCTTTGCGTGTAGCTATGGAAGT 2481 TGCATAATTATTATTATTATTATTATAACAAGTGTGTCTTACGTGCCACCACGGCGTTGTACCTGTAGGACTCTCATTCG 2561 GGATGATTGGAATAGCTTCTGGAATTTGTTCAAGTTTTGGGTATGTTTAATCTGTTATGTACTAGTGTTCTGTTTGTTAT 2641 TGTTTTGTTAATTACACCATAATGCTAATTTAAAGAGACTCCAAATCTCAATGAAGCCAGCTCACAGTGCTGTGTGCCCC 2721 GGTCACCTAGCAAGCTGCCGAACCAAAAGAATTTGCACCCCGCTGCGGGCCCACGTGGTTGGGGCCCTGCCCTGGCAGGG 2801 TCATCCTGTGCTCGGAGGCCATCTCGGGCACAGGCCCACCCCGCCCCACCCCTCCAGAACACGGCTCACGCTTACCTCAA 2881 CCATCCTGGCTGCGGCGTCTGTCTGAACCACGCGGGGGCCTTGAGGGACGCTTTGTCTGTCGTGATGGGGCAAGGGCACA 2961 AGTCCTGGATGTTGTGTGTATCGAGAGGCCAAAGGCTGGTGGCAAGTGCACGGGGCACAGCGGAGTCTGTCCTGTGACGC 3041 GCAAGTCTGAGGGTCTGGGCGGCGGGCGGCTGGGTCTGTGCATTTCTGGTTGCACCGCGGCGCTTCCCAGCACCAACATG 3121 TAACCGGCATGTTTCCAGCAGAAGACAAAAAGACAAACATGAAAGTCTAGAAATAAAACTGGTAAAACCCCAAAAAAAAA 3201 AAAAAAA Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | TZM-bl | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in GSM1462574. RNA binding protein: AGO2. Condition:TZM-bl ami BaL
... - Whisnant AW; Bogerd HP; Flores O; Ho P; et al., 2013, mBio. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Whisnant AW; Bogerd HP; Flores O; Ho P; et al. - mBio, 2013
UNLABELLED: The question of how HIV-1 interfaces with cellular microRNA (miRNA) biogenesis and effector mechanisms has been highly controversial. Here, we first used deep sequencing of small RNAs present in two different infected cell lines (TZM-bl and C8166) and two types of primary human cells (CD4(+) peripheral blood mononuclear cells [PBMCs] and macrophages) to unequivocally demonstrate that HIV-1 does not encode any viral miRNAs. Perhaps surprisingly, we also observed that infection of T cells by HIV-1 has only a modest effect on the expression of cellular miRNAs at early times after infection. Comprehensive analysis of miRNA binding to the HIV-1 genome using the photoactivatable ribonucleoside-induced cross-linking and immunoprecipitation (PAR-CLIP) technique revealed several binding sites for cellular miRNAs, a subset of which were shown to be capable of mediating miRNA-mediated repression of gene expression. However, the main finding from this analysis is that HIV-1 transcripts are largely refractory to miRNA binding, most probably due to extensive viral RNA secondary structure. Together, these data demonstrate that HIV-1 neither encodes viral miRNAs nor strongly influences cellular miRNA expression, at least early after infection, and imply that HIV-1 transcripts have evolved to avoid inhibition by preexisting cellular miRNAs by adopting extensive RNA secondary structures that occlude most potential miRNA binding sites. IMPORTANCE: MicroRNAs (miRNAs) are a ubiquitous class of small regulatory RNAs that serve as posttranscriptional regulators of gene expression. Previous work has suggested that HIV-1 might subvert the function of the cellular miRNA machinery by expressing viral miRNAs or by dramatically altering the level of cellular miRNA expression. Using very sensitive approaches, we now demonstrate that neither of these ideas is in fact correct. Moreover, HIV-1 transcripts appear to largely avoid regulation by cellular miRNAs by adopting an extensive RNA secondary structure that occludes the ability of cellular miRNAs to interact with viral mRNAs. Together, these data suggest that HIV-1, rather than seeking to control miRNA function in infected cells, has instead evolved a mechanism to become largely invisible to cellular miRNA effector mechanisms.
LinkOut: [PMID: 23592263]
|
Experimental Support 2 for Functional miRNA-Target Interaction | |||||||
---|---|---|---|---|---|---|---|
miRNA:Target | ---- | ||||||
Validation Method |
|
||||||
Conditions | HCT116 | ||||||
Location of target site | 3'UTR | ||||||
Tools used in this research | TargetScan , miRTarCLIP , Piranha | ||||||
Original Description (Extracted from the article) |
...
PAR-CLIP data was present in ERX177627. RNA binding protein: AGO2. Condition:p53_D_AGO_CLIP_4_5
... - Krell J; Stebbing J; Carissimi C; Dabrowska et al., 2016, Genome research. |
||||||
miRNA-target interactions (Provided by authors) |
|
||||||
Article |
- Krell J; Stebbing J; Carissimi C; Dabrowska et al. - Genome research, 2016
DNA damage activates TP53-regulated surveillance mechanisms that are crucial in suppressing tumorigenesis. TP53 orchestrates these responses directly by transcriptionally modulating genes, including microRNAs (miRNAs), and by regulating miRNA biogenesis through interacting with the DROSHA complex. However, whether the association between miRNAs and AGO2 is regulated following DNA damage is not yet known. Here, we show that, following DNA damage, TP53 interacts with AGO2 to induce or reduce AGO2's association of a subset of miRNAs, including multiple let-7 family members. Furthermore, we show that specific mutations in TP53 decrease rather than increase the association of let-7 family miRNAs, reducing their activity without preventing TP53 from interacting with AGO2. This is consistent with the oncogenic properties of these mutants. Using AGO2 RIP-seq and PAR-CLIP-seq, we show that the DNA damage-induced increase in binding of let-7 family members to the RISC complex is functional. We unambiguously determine the global miRNA-mRNA interaction networks involved in the DNA damage response, validating them through the identification of miRNA-target chimeras formed by endogenous ligation reactions. We find that the target complementary region of the let-7 seed tends to have highly fixed positions and more variable ones. Additionally, we observe that miRNAs, whose cellular abundance or differential association with AGO2 is regulated by TP53, are involved in an intricate network of regulatory feedback and feedforward circuits. TP53-mediated regulation of AGO2-miRNA interaction represents a new mechanism of miRNA regulation in carcinogenesis.
LinkOut: [PMID: 26701625]
|
CLIP-seq Support 1 for dataset GSM1462574 | |
---|---|
Method / RBP | PAR-CLIP / AGO2 |
Cell line / Condition | TZM-bl / TZM-bl ami BaL |
Location of target site | ENST00000227507.2 | 3UTR | AACACGGCUCACGCUUACCUCAACCAUCCUGGCUG |
Tools used in this analysis | TargetScan, miRTarCLIP, and Piranha |
Article / Accession Series | PMID: 23592263 / GSE59944 |
CLIP-seq Viewer | Link |
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
62 hsa-miR-758-5p Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT085323 | MORC3 | MORC family CW-type zinc finger 3 | 2 | 2 | ||||||||
MIRT089441 | STAMBP | STAM binding protein | 2 | 2 | ||||||||
MIRT089456 | TET3 | tet methylcytosine dioxygenase 3 | 2 | 2 | ||||||||
MIRT111856 | CCND1 | cyclin D1 | 2 | 2 | ||||||||
MIRT184933 | ZNF268 | zinc finger protein 268 | 2 | 2 | ||||||||
MIRT215288 | CREBRF | CREB3 regulatory factor | 2 | 2 | ||||||||
MIRT237300 | LPP | LIM domain containing preferred translocation partner in lipoma | 2 | 2 | ||||||||
MIRT238446 | MYO10 | myosin X | 2 | 4 | ||||||||
MIRT273827 | RPL41 | ribosomal protein L41 | 2 | 2 | ||||||||
MIRT282703 | HOOK1 | hook microtubule tethering protein 1 | 2 | 2 | ||||||||
MIRT347970 | ZNF850 | zinc finger protein 850 | 2 | 2 | ||||||||
MIRT371076 | KLF3 | Kruppel like factor 3 | 2 | 2 | ||||||||
MIRT464339 | USP6NL | USP6 N-terminal like | 2 | 2 | ||||||||
MIRT470034 | PTP4A1 | protein tyrosine phosphatase type IVA, member 1 | 2 | 2 | ||||||||
MIRT477506 | ELL2 | elongation factor for RNA polymerase II 2 | 2 | 2 | ||||||||
MIRT482886 | CACNA2D3 | calcium voltage-gated channel auxiliary subunit alpha2delta 3 | 2 | 2 | ||||||||
MIRT492606 | POLR3E | RNA polymerase III subunit E | 2 | 2 | ||||||||
MIRT502294 | GNG12 | G protein subunit gamma 12 | 2 | 6 | ||||||||
MIRT507600 | DCTN4 | dynactin subunit 4 | 2 | 4 | ||||||||
MIRT510728 | SON | SON DNA binding protein | 2 | 6 | ||||||||
MIRT514065 | KCNJ6 | potassium voltage-gated channel subfamily J member 6 | 2 | 8 | ||||||||
MIRT519718 | ZNF512B | zinc finger protein 512B | 2 | 4 | ||||||||
MIRT520890 | STRN | striatin | 2 | 2 | ||||||||
MIRT521760 | PPIL1 | peptidylprolyl isomerase like 1 | 2 | 6 | ||||||||
MIRT526874 | ERCC8 | ERCC excision repair 8, CSA ubiquitin ligase complex subunit | 2 | 2 | ||||||||
MIRT530232 | WSB2 | WD repeat and SOCS box containing 2 | 2 | 2 | ||||||||
MIRT532003 | ACTR2 | ARP2 actin related protein 2 homolog | 2 | 2 | ||||||||
MIRT533371 | UBE2D4 | ubiquitin conjugating enzyme E2 D4 (putative) | 2 | 4 | ||||||||
MIRT547106 | PIGW | phosphatidylinositol glycan anchor biosynthesis class W | 2 | 2 | ||||||||
MIRT548189 | FOXA1 | forkhead box A1 | 2 | 2 | ||||||||
MIRT552935 | VKORC1L1 | vitamin K epoxide reductase complex subunit 1 like 1 | 2 | 2 | ||||||||
MIRT560085 | ZNF195 | zinc finger protein 195 | 2 | 2 | ||||||||
MIRT561726 | PPP2CA | protein phosphatase 2 catalytic subunit alpha | 2 | 2 | ||||||||
MIRT562713 | ZNF415 | zinc finger protein 415 | 2 | 2 | ||||||||
MIRT562761 | ZNF846 | zinc finger protein 846 | 2 | 2 | ||||||||
MIRT564159 | ZNF117 | zinc finger protein 117 | 2 | 2 | ||||||||
MIRT565673 | SETD5 | SET domain containing 5 | 2 | 2 | ||||||||
MIRT565718 | SESN3 | sestrin 3 | 2 | 2 | ||||||||
MIRT566026 | RFX1 | regulatory factor X1 | 2 | 2 | ||||||||
MIRT569048 | ZNF655 | zinc finger protein 655 | 2 | 2 | ||||||||
MIRT570367 | UBE2V1 | ubiquitin conjugating enzyme E2 V1 | 2 | 2 | ||||||||
MIRT570410 | TMEM189-UBE2V1 | TMEM189-UBE2V1 readthrough | 2 | 2 | ||||||||
MIRT570443 | TMEM189 | transmembrane protein 189 | 2 | 2 | ||||||||
MIRT571738 | RNF11 | ring finger protein 11 | 2 | 2 | ||||||||
MIRT575042 | Tpgs2 | tubulin polyglutamylase complex subunit 2 | 2 | 4 | ||||||||
MIRT614330 | ZDHHC22 | zinc finger DHHC-type containing 22 | 2 | 2 | ||||||||
MIRT617629 | RAB3IP | RAB3A interacting protein | 2 | 2 | ||||||||
MIRT621667 | UBE4B | ubiquitination factor E4B | 2 | 2 | ||||||||
MIRT639906 | SRGAP2 | SLIT-ROBO Rho GTPase activating protein 2 | 2 | 2 | ||||||||
MIRT651436 | XRCC5 | X-ray repair cross complementing 5 | 2 | 2 | ||||||||
MIRT683853 | ZNF208 | zinc finger protein 208 | 2 | 2 | ||||||||
MIRT684841 | TPGS2 | tubulin polyglutamylase complex subunit 2 | 2 | 5 | ||||||||
MIRT689347 | ZNF83 | zinc finger protein 83 | 2 | 2 | ||||||||
MIRT692492 | SPIN4 | spindlin family member 4 | 2 | 2 | ||||||||
MIRT695711 | OLA1 | Obg like ATPase 1 | 2 | 2 | ||||||||
MIRT698219 | TMEM248 | transmembrane protein 248 | 2 | 2 | ||||||||
MIRT711560 | FAM20B | FAM20B, glycosaminoglycan xylosylkinase | 2 | 2 | ||||||||
MIRT712867 | TMEM67 | transmembrane protein 67 | 2 | 2 | ||||||||
MIRT722956 | TSPAN1 | tetraspanin 1 | 2 | 2 | ||||||||
MIRT723622 | SOBP | sine oculis binding protein homolog | 2 | 2 | ||||||||
MIRT724176 | ABCF2 | ATP binding cassette subfamily F member 2 | 2 | 2 | ||||||||
MIRT755363 | LMBR1 | limb development membrane protein 1 | 3 | 1 |
miRNA-Drug Associations | |||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|